silybin Encyclopedia — Scientific Background

What Is Silybin?

Silybin (CAS 22888-70-6), also known as silibinin, is the major flavonolignan of silymarin, a flavonoid complex extracted from the seeds of Silybum marianum (L.) Gaertn., commonly known as milk thistle. It is a mixture of two diastereomers (silybin A and silybin B) present in a 1:1 ratio, accounting for 60–70% of the total silymarin content. Silybin is chemically characterized by the molecular formula C₂₅H₂₂O₁₀ and a molecular weight of 482.44 g/mol.

Botanical Source

Silybin is extracted from the dried ripe fruit (seeds) of Silybum marianum (L.) Gaertn., a plant in the Asteraceae family native to the Mediterranean region. The active complex is a lipophilic extract from the seeds, composed of three isomer flavonolignans (silybin, silydianin, and silychristine), collectively known as silymarin. Silybin is the most active component, accounting for 60–70% of the total silymarin content and is considered the marker compound of silymarin.

Mechanisms of Action

Hepatoprotective Mechanisms — Multiple Pathways

Silybin‘s hepatoprotective activity operates through several complementary mechanisms:

• Hepatocyte Membrane Protection — Binding to hepatocyte membrane proteins, inhibiting lipid peroxidation to stabilize membrane permeability, supporting the liver’s synthesis of protective substances, and preventing damage from harmful substances

• Glutathione Enhancement — Reduction of glutathione oxidation to enhance its level in the liver and intestine

• Antioxidant Activity — Scavenging of prooxidant free radicals and inhibition of lipid peroxidation

• Protein Synthesis Stimulation — Stimulation of ribosomal RNA polymerase and subsequent protein synthesis, leading to enhanced hepatocyte regeneration

Antioxidant Defense — Nrf2/Keap1/HO-1 Pathway

A study published in Molecular Pharmaceutics (2025) demonstrated that silibinin-loaded liposomes (SUL) effectively inhibited alcohol-induced liver damage, oxidative stress, and fat accumulation. The formulation regulated the expression of Kelch-like ECH-associated protein 1 (Keap1), nuclear factor erythroid 2-related factor 2 (Nrf2), and heme oxygenase 1 (HO-1) proteins, thereby exerting antioxidative stress effects.

Anti-Fibrotic Activity

Silymarin and silibinin delayed hepatic stellate cell activation, probably due to inhibition of NF-κB activation. The beneficial effect of high doses of silymarin (200 mg/kg) on fibrosis may be due to promotion of hepatic stellate cell apoptosis. Silymarin also controls inflammation, enhances glucuronidation, and protects against glutathione depletion.

Anti-Inflammatory and Anti-Apoptotic Effects

Silibinin-loaded liposomes modulated apoptosis-related factors, including B-cell lymphoma-2 (Bcl-2), BCL-2-associated X (Bax), cysteinyl aspartate specific proteinase-3 (Caspase-3), and cleaved caspase-3, to mitigate hepatocyte apoptosis.

The Bioavailability Challenge

Despite its broad pharmacological potential, native silybin presents significant formulation challenges. The compound has extremely poor water solubility, low permeability, and poor bioavailability. Approximately 20% to 50% of its active components are absorbed after oral administration, with about 80% secreted via bile and 10% entering the enterohepatic circulation, resulting in an oral bioavailability of just 0.73%. Silybin is poorly water-soluble, and only 20–50% is absorbed from the gut.

These limitations have driven the development of advanced delivery systems, including phytosomes, liposomes, nanoparticles, and solid dispersions. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing silybin bioavailability and hepatoprotective efficacy.

Liposomal Silybin

Liposomal encapsulation of silybin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the silybin molecule, forming a protective shell that enhances solubility, stability, and cellular uptake. This delivery system:

• Achieves a 3.5-fold higher oral bioavailability compared to silymarin suspension

• Enhances hepatoprotection efficacy by 1.5-fold in vitro

• Prevents ROS production by 10-fold in LPS-induced macrophages

• Provides targeted delivery to hepatocytes and inflammatory cells

• Achieves 89% encapsulation efficiency with sustained release of 80% within 20 hours

An optimized silybin liposome formulation using phosphatidylcholine and cholesterol (molar ratio 9:1) was prepared by thin film hydration technique. The optimized formulation exhibited a vesicle size of 276 nm, 89% encapsulation efficiency, and sustained drug release of 80% within 20 hours. Animal studies demonstrated superior hepatoprotective effect compared to silybin solution.

A separate study using a lecithin-based phytosomal-liposomal formulation of silymarin achieved a 3.5-fold higher oral bioavailability compared to silymarin suspension, with 1.5-fold better hepatoprotection and 10-fold better ROS prevention in vitro. In an in vivo paracetamol-induced hepatotoxicity model in Wistar rats, the formulation was more efficacious than silymarin suspension in protecting the liver and reducing associated inflammatory conditions.

Clinical Evidence

Liver Disease — Clinical Trials

Based on clinical trials, the recommended dose is 280 to 420 mg of a standardized silymarin preparation (calculated as silybin). Treatment for 1–3 months may be required before the therapeutic effects are apparent. A 2007 Cochrane review of 13 randomized clinical trials assessed milk thistle in 915 patients with alcoholic and/or hepatitis B or C virus liver diseases. Silymarin has been approved in different doses for the treatment or adjuvant therapy for liver disorders by regulatory authorities of different countries.

Type 2 Diabetes — Glycemic Control

A randomized controlled trial in people with type 2 diabetes demonstrated that 200 mg of silymarin taken three times a day before meals resulted in a significant reduction in blood glucose and glycated hemoglobin (HbA1c) levels compared to placebo. A daily intake of 600 mg of silymarin (divided into three doses) for 6 months was associated with a significant reduction in fasting glucose and mean daily glucose levels from the second month of treatment onwards.

NAFLD/MASLD — Cochrane Meta-Analysis

A 2025 Cochrane meta-analysis included 17 randomized clinical trials with 2,069 participants having metabolic dysfunction–associated steatotic liver disease (MASLD). A prospective single-arm study in NAFLD and metabolic syndrome patients used 140 mg of silymarin thrice daily for 6 months with lifestyle intervention.

Alcoholic Liver Disease — Preclinical Evidence

A study published in Molecular Pharmaceutics (2025) demonstrated that silibinin-loaded liposomes (SUL) effectively inhibited alcohol-induced liver damage, oxidative stress, and fat accumulation. The formulation regulated the Keap1/Nrf2/HO-1 pathway and modulated apoptosis-related factors to mitigate hepatocyte apoptosis, demonstrating enhanced therapeutic efficacy against alcoholic liver disease.

Safety and Regulatory

Silymarin and silybin are generally well tolerated. Based on clinical trials, adverse reactions are limited to gastrointestinal disturbances, such as nausea and diarrhea. No drug interactions have been reported.

Regulatory status varies by region:

• United States — Milk thistle extract is regulated as a dietary supplement. The FDA does not require registration or approval for dietary supplements. Milk thistle extract is generally recognized as safe for intended uses (GRAS Self-Determined).

• European Union — In 2018, the European Medicines Agency (EMA) evaluated Silybum marianum (L.) Gaertn., fructus for traditional medicinal use. The Committee on Herbal Medicinal Products (HMPC) of the EMA released a monograph concluding that milk thistle preparations are safe and efficient to be used.

• China — Milk thistle has been included in the Pharmacopoeia of the People‘s Republic of China with defined quality standards.

• Other Regions — Silymarin has been approved in different doses for the treatment or adjuvant therapy for liver disorders by regulatory authorities of different countries.

Testing protocols must adhere to international standards including USP (Powdered Milk Thistle Extract monograph), European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

488$/KG

388$/KG